Back to top
more

Orthofix Medical (OFIX)

(Delayed Data from NSDQ)

$12.31 USD

12.31
847,214

+1.46 (13.46%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $12.32 +0.01 (0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Orthofix (OFIX) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Orthofix (OFIX) delivered earnings and revenue surprises of +225.00% and +3.51%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Idexx Laboratories (IDXX) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Idexx (IDXX) delivered earnings and revenue surprises of +9.67% and +4.01%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Orthofix (OFIX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Orthofix (OFIX) delivered earnings and revenue surprises of 52.94% and 1.87%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Intuitive Surgical, Inc. (ISRG) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Intuitive Surgical (ISRG) delivered earnings and revenue surprises of 5.85% and 3.27%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Globus Medical Expands Anterior Spine Portfolio With Two New Offerings

by Zacks Equity Research

GMED announces the commercial launch of COHERE ALIF Spacer and Modulus ALIF Blades.

Zacks Equity Research

Orthofix (OFIX) Q4 Earnings Lag Estimates

by Zacks Equity Research

Orthofix (OFIX) delivered earnings and revenue surprises of -66.67% and 1.53%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Orthofix (OFIX) Q3 Earnings Surpass Estimates

by Zacks Equity Research

Orthofix (OFIX) delivered earnings and revenue surprises of 150% and 0%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Globus Medical Expands Orthopedic Trauma Portfolio With New Launches

by Zacks Equity Research

GMED launches ANTHEM II Distal Radius Volar Plates, AUTOBAHN Trochanteric Nail PRO Instruments and CAPTIVATE SOLA Headless Screws.

Zacks Equity Research

Zimmer Biomet's (ZBH) Latest Deal to Expand Its Hip Portfolio

by Zacks Equity Research

Zimmer Biomet (ZBH) announces the acquisition of OrthoGrid to expand its hip portfolio with an AI-driven surgical guidance system.

Zacks Equity Research

Orthofix (OFIX) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Orthofix (OFIX) delivered earnings and revenue surprises of 138.46% and 1.47%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Orthofix Medical's (OFIX) Fitbone System Gets FDA Clearance

by Zacks Equity Research

Orthofix Medical (OFIX) announces the FDA clearance and first U.S. implant of the Fitbone Transport and Lengthening System, used to treat large bone defects in the femur and tibia.

Zacks Equity Research

Orthofix Medical's (OFIX) Telescopic Nail Gets FDA Clearance

by Zacks Equity Research

Orthofix Medical (OFIX) announces the FDA clearance of its Rodeo Telescopic Nail, which is likely to aid in curing fractures or abnormalities in individuals with osteogenesis imperfecta.

Zacks Equity Research

Avanos Medical (AVNS) Q1 Earnings Beat Estimates (Revised)

by Zacks Equity Research

Avanos Medical (AVNS) delivered earnings and revenue surprises of +4.76% and 1.65%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Avanos Medical (AVNS) Q1 Earnings Lag Estimates

by Zacks Equity Research

Avanos Medical (AVNS) delivered earnings and revenue surprises of -9.52% and 1.65%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Orthofix (OFIX) Q4 Earnings Beat Estimates, Gross Margin Up

by Zacks Equity Research

Orthofix's (OFIX) fourth-quarter earnings and revenues beat their respective consensus estimate. Gross margin expands while the company continues to incur losses at the operating level.

Zacks Equity Research

Orthofix (OFIX) Releases New Data for Spinal Fusion Procedures

by Zacks Equity Research

According to Orthofix (OFIX), this data highlights the noninvasive and cost-effective nature of SpinalStim, enabling patients to continue their healing in the comfort of their homes.

Zacks Equity Research

Wall Street Analysts Believe Orthofix (OFIX) Could Rally 72.19%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 72.2% in Orthofix (OFIX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Orthofix (OFIX) Q3 Earnings Top Estimates, 2023 Sales View Cut

by Zacks Equity Research

Orthofix (OFIX) saw very strong growth across multiple business segments and product lines in Q3.

Zacks Equity Research

Does Orthofix (OFIX) Have the Potential to Rally 78.73% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 78.7% in Orthofix (OFIX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Paragon 28, Inc. (FNA) Surges 12.1%: Is This an Indication of Further Gains?

by Zacks Equity Research

Paragon 28, Inc. (FNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Hologic (HOLX) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Hologic (HOLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Orthofix (OFIX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Orthofix (OFIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Orthofix (OFIX) Secures FDA 510k Clearance for OsteoCove Graft

by Zacks Equity Research

Orthofix (OFIX) announces the full commercial availability of the OsteoCove synthetic graft after gaining the FDA's nod.

Zacks Equity Research

Orthofix (OFIX) Soars 6.4%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Orthofix (OFIX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Orthofix (OFIX) Unveils Gemini System, Advances in Trauma Wing

by Zacks Equity Research

According to Orthofix (OFIX), with the launch of the Galaxy Fixation Gemini system surgeons now have efficient solutions for lower extremity trauma scenarios where time is an important factor.